AMLX Stock Price | Amylyx Pharmaceuticals Inc P/E, Revenue, EPS, & Forecasts

Amylyx Pharmaceuticals Inc • AMLX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Amylyx Pharmaceuticals Inc

Ticker

AMLX

Trading on

NASDAQ

ISIN

US0321085088

Industry

Biotechnology

Sector

Healthcare

CEO

Joshua B. Cohen

Headquarters

43 Thorndike Street, Cambridge, MA, United States, 02141

Employees

123

Website

https://amylyx.com

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Metrics

BasicAdvanced

Market cap

$323M

P/E ratio

EPS

-$4.43

Dividend Yield

0.00%

Beta

-0.51

Forward P/E ratio

2.77

EBIDTA

$-291M

Ex dividend date

Price & volume

Market cap

$323M

Average daily volume

0.8M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

2.77

PEG ratio

Trailing P/E

Price to sales

3.7

Price to book

1.96

Earnings

EPS

-$4.43

EPS estimate (current quarter)

-$0.59

EPS estimate (next quarter)

-$0.62

EBITDA

$-291M

Revenues (TTM)

$87.4M

Revenues per share (TTM)

$1.28

Technicals

Beta

-0.51

52-week High

$7.27

52-week Low

$1.58

50-day moving average

$3.51

200-day moving average

$3.32

Short ratio

5.13

Short %

4.43%

Management effectiveness

ROE (TTM)

100.88%

ROA (TTM)

51.31%

Profit margin

0.00%

Gross profit margin

$-141M

Operating margin

6,113.38%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

99.60%

Share stats

Outstanding Shares

88.6M

Float

59.5M

Insiders %

11.70%

Institutions %

65.72%

Analyst Insights & forecasts

50% Buy

50% Hold

0% Sell

Based on information from 6 analysts.

Average price target

$8.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.12

-$0.01

1,100.00%

Q1 • 24Beat

-$0.73

Q2 • 24Beat

-$1.07

-$0.92

16.94%

Q3 • 24Beat

-$0.55

-$0.59

6.78%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.4M

$-72.7M

17,476.92%

Q3 • 24

$-0.7M

$-37.5M

5,646.02%

Q4 • 24

259.86%

48.36%

132.31%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$251M

$54.5M

21.74%

Q3 • 24

$194M

$28.9M

14.91%

Q4 • 24

22.77%

47.04%

31.43%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-41.6M

$38.8M

$0.1M

$-41.6M

Q3 • 24

$-59M

$65M

$0.1M

$-59M

Q4 • 24

41.95%

67.41%

37.50%

42.06%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Amylyx Pharmaceuticals Inc share?

Amylyx Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Amylyx Pharmaceuticals Inc have?

Amylyx Pharmaceuticals Inc currently has 88.6M shares.

Does Amylyx Pharmaceuticals Inc pay dividends?

No, Amylyx Pharmaceuticals Inc doesn't pay dividends.

What is Amylyx Pharmaceuticals Inc 52 week high?

Amylyx Pharmaceuticals Inc 52 week high is $7.27.

What is Amylyx Pharmaceuticals Inc 52 week low?

Amylyx Pharmaceuticals Inc 52 week low is $1.58.

What is the 200-day moving average of Amylyx Pharmaceuticals Inc?

Amylyx Pharmaceuticals Inc 200-day moving average is $3.32.

Who is Amylyx Pharmaceuticals Inc CEO?

The CEO of Amylyx Pharmaceuticals Inc is Joshua B. Cohen.

How many employees Amylyx Pharmaceuticals Inc has?

Amylyx Pharmaceuticals Inc has 123 employees.

What is the market cap of Amylyx Pharmaceuticals Inc?

The market cap of Amylyx Pharmaceuticals Inc is $323M.

What is the P/E of Amylyx Pharmaceuticals Inc?

The current P/E of Amylyx Pharmaceuticals Inc is null.

What is the EPS of Amylyx Pharmaceuticals Inc?

The EPS of Amylyx Pharmaceuticals Inc is -$4.43.

What is the PEG Ratio of Amylyx Pharmaceuticals Inc?

The PEG Ratio of Amylyx Pharmaceuticals Inc is null.

What do analysts say about Amylyx Pharmaceuticals Inc?

According to the analysts Amylyx Pharmaceuticals Inc is considered a buy.